The NHS Cancer Alliance responsible for optimising cancer services across Somerset, Wiltshire, Avon and Gloucestershire will become the first in the United Kingdom to implement a new AI technology from Inspirata designed to accelerate the process by which patients with cancer are identified and matched with relevant clinical trials.
Bristol, United Kingdom, Feb. 10, 2022software at University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), as the first step of a multi-site roll-out of the clinical trial matching solution for the benefit of patients across the geography. This initiative is part of the alliance's long-standing aim of improving clinical trial access.
"We are excited to partner with Inspirata in implementing Trial Navigator," said Dr Helen Winter, Clinical Director of SWAG Cancer Alliance. "We hope that this solution will afford both clinicians and patients in the region a greater choice of potential treatment options. Similarly, expedite the fulfilment of existing, and the hosting of new clinical trials as we look to recover services affected by the pandemic."
Trial Navigator draws on oncology-specific natural language processing (NLP) AI to eliminate common bottlenecks within the trial matching workflow by working with the Trust's existing information governance processes to search the individual medical reports, notes and referral letters of patients with cancer, abstracting key information about their disease and automatically cross-referencing attributes identified against study eligibility criteria held within clinical trial databases. The software then immediately surfaces studies most likely to represent a patient-fit for clinical evaluation.
"Clinical trials are an integral part of the optimal management of cancer patients but having a complete and up-to-date picture of the ever-changing trial landscape can be time-consuming," said Dr Axel Walther, Clinical Trials Unit Lead at Bristol Haematology and Oncology Centre, UHBW."Working with Inspirata to automate this aspect of the oncology workflow means our clinical teams can spend more time with patients evaluating potential trial options to best suit them. More patients will be able to take part in trials relevant to their cancer, increasing treatment options and driving innovation."
It is also hoped that the introduction of Trial Navigator will help to assist in recruiting a wider demographic of patients to take part in cancer research, as a recent audit has shown that some cohorts of patients are less likely to participate in clinical trials than others. It is anticipated that this software will bring opportunities forward and medical teams will be able to offer these to patients more readily.
"Recent evidence points to a myriad of factors contributing to the under-representation of different groups in cancer studies. This can include pressures on healthcare professionals' workload, time constraints and lack of trial information," further explained Helen Winter. "The implementation of Trial Navigator is designed to help our care teams extend access to cancer research to everyone within our community wishing to take advantage."
Automation of clinical trial matching will also assist the SWAG Cancer Alliance in working towards NHS England's defined aims for the building-back of cancer services following Covid-19.
"NHS England detailed the tackling of inequalities and utilising innovations in practice as key strategic points of its Cancer Service Recovery Plan ," said Dr Adam Dangoor, Chief Clinical Information Officer at UHBW. "In engaging Inspirata we are addressing a long-standing aim of our Cancer Alliance of ensuring more patients are put forward for trial. In addition, making our pathways more efficient and automatic so we can provide the most effective care for our patients."
Oenone Duroe, General Manager Inspirata Europe, said: "Inspirata is thrilled to have been afforded the opportunity to work with the SWAG Cancer Alliance and is excited to help the region cement its reputation for innovation and clinical trial excellence."
Inspirata's engagement with the SWAG Cancer Alliance follows an equivalent collaboration with Guy's and St Thomas', King's Health Partners Experimental Cancer Medical Centre and Cancer Research UKaround automated patient matching with early-phase clinical trials.
ENDS
About Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance
The Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance is the forum to bring providers and commissioners together with patients, to co-design services to optimise pathways, ensure effective integration and address variation, and are the vehicle that leads the activity required at a local level to meet the 2023/24 ambitions set out by the Cancer Taskforce.
The Cancer Alliance puts clinical leaders across primary, secondary, and tertiary care in the driving seat for improving quality and outcomes across cancer pathways, based on shared data and metrics. Continuing to deliver the strategy and its programmes will require committed leadership, smart choices around investing to save, and a firm intent to try new approaches and test new models of care.
About Inspirata Europe Ltd.
Inspirata Europe helps patients fighting cancer-and the clinicians they trust-to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship.
Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring users the broadest oncology informatics platform available globally. To learn more, visit www.inspirata.com.
Attachments
- University Hospitals Bristol and Weston NHS Foundation Trust (https://ml.globenewswire.com/Resource/Download/15a06739-7b31-43c5-90af-44271f556b63)
- Trial Navigator User Interface (https://ml.globenewswire.com/Resource/Download/53682ca9-24fd-43b5-8c08-b0231b36b56d)
